Home > Healthcare > Pharmaceuticals > Finished Drug Form > Pain Relief Patches Market

Pain Relief Patches Market Trends

Report ID: GMI10077
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Pain Relief Patches Market Trends

As populations age globally, the prevalence of chronic conditions such as arthritis and back pain is increasing. Pain relief patches offer a convenient and effective solution for managing persistent pain without the side effects associated with oral medications. Advances in transdermal drug delivery systems enhance the penetration of active ingredients through the skin, improving the efficacy and duration of pain relief. Consumers increasingly prefer non-invasive treatments that minimize systemic side effects. Pain relief patches offer localized therapy directly to the affected area, enhancing patient comfort and compliance.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of pain relief patches reached USD 3.9 billion in 2023 and will witness 6.2% CAGR between 2024 and 2032, propelled by the rising prevalence of chronic pain conditions, including arthritis and back pain, and increasing awareness of non-invasive pain management solutions.

The muscle pain application segment achieved 41% of the pain relief patches industry share in 2023 due to the widespread prevalence of muscle pain from physical activity, sports injuries, and aging.

North America market will record USD 1.8 billion by 2032, owing to the advanced technological capabilities and significant investment in R&D, high prevalence of chronic pain conditions and the strong healthcare infrastructure.

Some of the leading industry players include 3M Health Care, Actavis, Chattem, Inc., Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Mylan N.V., Novartis AG, Pfizer Inc., Reckitt Benckiser Group plc, Salonpas, Sanofi, and Teva Pharmaceutical Industries Ltd. among others.